Rwanda Recalls French-Manufactured Aspirin Over Quality Concerns

Rwanda Food and Drugs Authority has announced an immediate recall of batch No. B6224 of Aspirine Vitamin C 330mg/200mg (effervescent tablets), manufactured by Union de pharmacologie scientifique appliquée (UPSA), a French pharmaceutical group, due to quality concerns.

https://x.com/RwandaFDA/status/1915041881060184424

In a statement issued on April 23, Rwanda FDA cited quality complaints about the affected batch produced in September 2024 and set to expire in August 2026.

"Rwanda FDA conducted investigations and found that the batch of the medicine indicated above had changed color from white to brown, compromising the product's quality standards," reads part of the statement.

Rwanda FDA ordered an immediate halt to the distribution and dispensing of the affected batch.

Importers, distributors, and health facilities are instructed to return the recalled products to their suppliers and report back to Rwanda FDA within 10 working days from the recall notice.

"The report must include the quantities imported or procured, distributed, returned, and the remaining stock."

Additionally, the public is advised to stop using any products from the recalled batch.

For further guidance, stakeholders and people in possession of the affected medicine are encouraged to contact Rwanda FDA.

AllAfrica publishes around 600 reports a day from more than 90 news organizations and over 500 other institutions and individuals, representing a diversity of positions on every topic. We publish news and views ranging from vigorous opponents of governments to government publications and spokespersons. Publishers named above each report are responsible for their own content, which AllAfrica does not have the legal right to edit or correct.

Articles and commentaries that identify allAfrica.com as the publisher are produced or commissioned by AllAfrica. To address comments or complaints, please Contact us.